FDA
-
-
-
-
-
-
-
ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences
-
-
-
-
-
-
-
ProSomnus (OSA) Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices
-
-
-
-
-
-
-
ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices
-
-
-
-
-
-
-
ProSomnus (OSA) Appoints Brian Dow as CFO
-
-
-
-
-
-
-
ProSomnus® Announces Completion of Enrollment in Antwerp University Hospital’s First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)
-
-
-
-
-
-
-
Study Published in "Military Medicine" Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

